BCWORLD PHARM. Co. Ltd (200780) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BCWORLD PHARM. Co. Ltd (200780) has a cash flow conversion efficiency ratio of 0.020x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩1.43 Billion ≈ $968.52K USD) by net assets (₩72.50 Billion ≈ $49.13 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
BCWORLD PHARM. Co. Ltd - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how BCWORLD PHARM. Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 200780 total liabilities for a breakdown of total debt and financial obligations.
BCWORLD PHARM. Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BCWORLD PHARM. Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MPC Energy Solutions NV
OL:MPCES
|
0.002x |
|
Green Critical Minerals Ltd
AU:GCM
|
-0.032x |
|
Heeros Oyj
HE:HEEROS
|
0.475x |
|
D P Wires Limited
NSE:DPWIRES
|
0.208x |
|
HLscience Co. Ltd
KQ:239610
|
-0.023x |
|
Focus Graphite Inc
V:FMS
|
2.166x |
|
Carbochim SA
RO:CBC
|
N/A |
|
Central Motek Co Ltd
KO:308170
|
-0.050x |
Annual Cash Flow Conversion Efficiency for BCWORLD PHARM. Co. Ltd (2015–2024)
The table below shows the annual cash flow conversion efficiency of BCWORLD PHARM. Co. Ltd from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see market value of BCWORLD PHARM. Co. Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩76.67 Billion ≈ $51.96 Million |
₩4.04 Billion ≈ $2.74 Million |
0.053x | -60.64% |
| 2023-12-31 | ₩81.64 Billion ≈ $55.33 Million |
₩10.94 Billion ≈ $7.41 Million |
0.134x | +54.84% |
| 2022-12-31 | ₩79.55 Billion ≈ $53.91 Million |
₩6.88 Billion ≈ $4.66 Million |
0.087x | +1237.07% |
| 2021-12-31 | ₩81.46 Billion ≈ $55.20 Million |
₩-619.83 Million ≈ $-420.05K |
-0.008x | +85.94% |
| 2020-12-31 | ₩101.69 Billion ≈ $68.92 Million |
₩-5.50 Billion ≈ $-3.73 Million |
-0.054x | -143.45% |
| 2019-12-31 | ₩97.24 Billion ≈ $65.90 Million |
₩12.11 Billion ≈ $8.21 Million |
0.125x | +110.10% |
| 2018-12-31 | ₩90.09 Billion ≈ $61.05 Million |
₩5.34 Billion ≈ $3.62 Million |
0.059x | -39.05% |
| 2017-12-31 | ₩81.23 Billion ≈ $55.05 Million |
₩7.90 Billion ≈ $5.35 Million |
0.097x | +2848.61% |
| 2016-12-31 | ₩73.88 Billion ≈ $50.06 Million |
₩243.66 Million ≈ $165.13K |
0.003x | -97.47% |
| 2015-12-31 | ₩67.40 Billion ≈ $45.68 Million |
₩8.78 Billion ≈ $5.95 Million |
0.130x | -- |
About BCWORLD PHARM. Co. Ltd
BCWORLD PHARM. Co., Ltd. operates as a pharmaceutical company in South Korea. The company provides products in various therapeutic areas comprising musculoskeletal system, digestive system, circulatory machine, central nervous system, adrenocorticosteroids, narcotic analgesics, erectile dysfunction treatment, wellbeing injection, diuretic, antitussive expectorant, vaginitis treatment, anti-tuberc… Read more